We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
Notice for tocilizumab (Roche Products Pty Limited)
Active ingredients
tocilizumab
Sponsor
Date of review outcome
Lapse date
Type
Provisional approval
Indication
Coronavirus disease 2019 (COVID-19) (IV formulation only) for the treatment of coronavirus disease 2019 (COVID-19) in hospitalised adults who are receiving systemic corticosteroids and require supplemental oxygen or mechanical ventilation
Therapeutic area
Infectious diseases